Dr. Plimack on Frontline Pembrolizumab for Urothelial Carcinoma

Elizabeth Plimack, MD
Published: Friday, Jul 07, 2017



Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the KEYNOTE-052 trial investigating pembrolizumab (Keytruda) in the frontline setting for patients with urothelial carcinoma.

The KEYNOTE-052 investigated pembrolizumab in the frontline setting, explains Plimack. Additionally, the PD-L1 biomarker and gene signature that predicted full response had been investigated in this trial.

The search for better biomarkers to help select treatment is still requires further investigation states Plimack.
 


Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the KEYNOTE-052 trial investigating pembrolizumab (Keytruda) in the frontline setting for patients with urothelial carcinoma.

The KEYNOTE-052 investigated pembrolizumab in the frontline setting, explains Plimack. Additionally, the PD-L1 biomarker and gene signature that predicted full response had been investigated in this trial.

The search for better biomarkers to help select treatment is still requires further investigation states Plimack.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x